Edgestream Partners L.P. lowered its holdings in Amedisys, Inc. (NASDAQ:AMED – Free Report) by 18.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 49,482 shares of the health services provider’s stock after selling 11,154 shares during the quarter. Edgestream Partners L.P.’s holdings in Amedisys were worth $4,560,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of the business. State Board of Administration of Florida Retirement System raised its holdings in shares of Amedisys by 5.3% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 38,403 shares of the health services provider’s stock valued at $3,539,000 after purchasing an additional 1,923 shares in the last quarter. Swiss National Bank raised its stake in shares of Amedisys by 5.4% during the 1st quarter. Swiss National Bank now owns 64,400 shares of the health services provider’s stock worth $5,935,000 after acquiring an additional 3,300 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Amedisys during the 1st quarter worth approximately $761,000. Texas Permanent School Fund Corp raised its stake in shares of Amedisys by 1.4% during the 1st quarter. Texas Permanent School Fund Corp now owns 28,560 shares of the health services provider’s stock worth $2,632,000 after acquiring an additional 381 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of Amedisys by 111.7% during the 1st quarter. BNP Paribas Financial Markets now owns 12,050 shares of the health services provider’s stock worth $1,111,000 after acquiring an additional 6,358 shares in the last quarter. Institutional investors own 94.36% of the company’s stock.
Analyst Ratings Changes
Several research firms recently commented on AMED. William Blair lowered shares of Amedisys from an “outperform” rating to a “market perform” rating in a research note on Monday, July 1st. StockNews.com upgraded shares of Amedisys from a “hold” rating to a “buy” rating in a research note on Saturday, May 4th. Cantor Fitzgerald reiterated a “neutral” rating and set a $101.00 price objective on shares of Amedisys in a research note on Thursday, April 25th. Raymond James reissued a “market perform” rating on shares of Amedisys in a research report on Tuesday, March 26th. Finally, Royal Bank of Canada boosted their target price on shares of Amedisys from $97.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 25th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $100.67.
Amedisys Price Performance
NASDAQ:AMED traded down $0.15 during trading hours on Monday, hitting $97.45. 286,258 shares of the company were exchanged, compared to its average volume of 315,354. Amedisys, Inc. has a 52-week low of $89.55 and a 52-week high of $98.46. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.31. The company’s 50 day moving average price is $94.63 and its 200-day moving average price is $93.68.
Amedisys (NASDAQ:AMED – Get Free Report) last released its quarterly earnings data on Wednesday, April 24th. The health services provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. The business had revenue of $571.41 million for the quarter, compared to the consensus estimate of $565.38 million. Amedisys had a negative net margin of 0.91% and a positive return on equity of 12.85%. The business’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.00 EPS. As a group, equities analysts anticipate that Amedisys, Inc. will post 4.57 earnings per share for the current fiscal year.
Amedisys Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Further Reading
- Five stocks we like better than Amedisys
- Industrial Products Stocks Investing
- Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Has This Leading Tech Stock Halted the AI Surge?
- 3 Warren Buffett Stocks to Buy Now
- Revolutionary Battery Stock Gains Momentum with 3D Silicon-Anodes
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMED – Free Report).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.